ASCO 2026

May 29 - June 02, 2026
Chicago, IL

American Society of Clinical Oncology Annual Meeting 2026
Explore more Oncology congress materials
Material Type

Results(12)

Oncology
Beamion BCGC-1: Four New Phase Ib/II Cohorts to Evaluate Oral Zongertinib With Other Agents in HER2-Positive Metastatic Breast Cancer (mBC) and Metastatic Colorectal Cancer (mCRC)
Author(s): Kohei Shitara, Izuma Nakayama, Shigehisa Kitano et al.
Combining Zanidatamab, FOLFOX, and Pembrolizumab as First-Line Therapy for HER2/PD-L1–Positive Gastroesophageal Adenocarcinoma – the phase ll IKF/AIO ZANGEA trial with translational analysis
Author(s): Joseph Tintelnot, Eray Gökkurt, Salah-Eddin Al-Batran et al.
Trial in Progress: A phase I/II study of safety/efficacy using lurbinectedin, combined with ipilimumab, and nivolumab for advanced soft tissue sarcomas (NCT05876715)​
Author(s): Samantha Jeffrey, Sant P. Chawla, Oliver Davidorf et al.
Comparison of Real-World Overall Survival Between Atezolizumab- and Durvalumab-Containing First‐Line Induction and Maintenance Regimens in Extensive-Stage Small Cell Lung Cancer
Author(s): Apar Kishor Ganti, Jeremy Snider, Jessie T Yan et al.
Safety and Pharmacokinetics of Lurbinectedin in Pediatric Patients With Relapsed/Refractory Solid Tumors and Preliminary Antitumor Activity in Pediatric and Young Adult Patients With Relapsed/Refractory Ewing Sarcoma: Results From a Phase 1 Study
Author(s): Julia Lynne Glade Bender, Joseph Gerald Pressey, Lars M Wagner et al.
Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the ​ Phase 3 IMforte study of lurbinectedin + atezolizumab maintenance treatment in extensive-stage ​ small-cell lung cancer
Author(s): Luis G. Paz-Ares, Hossein Borghaei, Martin Reck et al.
Real-world (RW) effectiveness and safety of lurbinectedin (lurbi) for previously treated extensive-stage small cell lung cancer (ES-SCLC): Final primary and subgroup analysis results of Jazz EMERGE 402
Author(s): Firas Benyamine Badin, Philip E Lammers, Geoffrey Liu et al.
IMforte: Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of FirstLine Maintenance Treatment With Lurbinectedin + Atezolizumab vs Atezolizumab in Extensive-Stage Small Cell Lung Cancer
Author(s): Hossein Borghaei, Luis Paz-Ares, Martin Reck et al.
Real-World Treatment Patterns and Overall Survival in Patients With HER2-Positive Advanced or Metastatic Gastroesophageal Adenocarcinomas in the US
Author(s): Farshid Dayyani, Xiaozhou Fan, Joan Zape et al.